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Background. Several studies in the last decades have focused on finding a precise method for the diagnosis of periodontal disease
in its early stages. Aim. To evaluate from current scientific literature the most common and precise method for gingival crevicular
fluid (GCF) sample collection, biomarker analytical methods, and the variability of biomarker quantification, even when using
the same analytical technique. Methodology. An electronic search was conducted on in vivo studies that presented clinical data
on techniques used for GCF collection and biomarker analysis. Results. The results showed that 71.1%, 24.7%, and 4.1% of the
studies used absorption, microcapillary, and washing techniques, respectively, in their gingival crevicular fluid collection. 73.1%
of the researchers analyzed their samples by using enzyme-linked immunosorbent assay (ELISA). 22.6%, 19.5%, and 18.5% of the
researchers included interleukin-1 beta (IL-1𝛽), matrix metalloproteinase-8 (MMP-8), and tumor necrosis factor-alpha (TNF-𝛼),
respectively, in their studies as biomarkers for periodontal disease. Conclusion. IL-1𝛽 can be considered among the most common
biomarkers that give precise results and can be used as an indicator of periodontal disease progression. Furthermore, paper strips
are the most convenient and accurate method for gingival crevicular fluid collection, while enzyme-linked immunosorbent assay
can be considered the most conventional method for the diagnosis of biofluids.
1. Introduction
The aim of this review is to evaluate GCF sampling, analytical
methods, and oral biomarkers used for the diagnosis and
monitoring of different periodontal diseases. It also attempts
to explore the main reasons for differences in biomarker
quantification among the investigators, by reviewing studies
based on inclusion and exclusion criteria from January 2005
to May 2015.
Periodontal diseases are multifactorial infections influ-
enced by the interaction of different types of bacteria with
host cells and tissues leading to the release of many cytokines
and chemokines which cause the destruction of the peri-
odontal structures [1]. GCF in subjects with periodontal
disease contains inflammatory cells, bacteria, tissue break-
down products, antibodies, and complement system proteins
and enzymes, in addition to many inflammatory mediators
[2]. GCF can be considered among the most nontraumatic
investigational methods used to provide information about
periodontal tissue conditions, including the status of the
connective tissue and the degree of hard tissue destruction
[3]. The severity of periodontal tissue inflammation can be
estimated by measuring proinflammatory indicators such as
IL-1, -6, and -8 and TNF-𝛼 that have an important role in the
pathogenesis of periodontal diseases [4].
Periodontal diseasesmust be described by a criteria that is
clear and suitable for any examiner to apply, so that the same
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diagnosis can be reached by other examiners under same
conditions [5]. The early diagnosis of periodontal diseases is
of significant importance that demands a quick, sensitive, and
precise chair-side analytical test [6, 7].
The methods of diagnosis should provide relevant infor-
mation to assist the differentiation among a variety of peri-
odontal diseases, the degree of periodontal tissue destruction,
and the prognosis of periodontal disease. Nowadays, the basic
methodused in the diagnosis of periodontal diseases depends
mainly on the measurement of the clinical periodontal
parameters including plaque score (PS) or plaque index (PI),
clinical attachment loss (CAL), probing depth (PD), gingival
index (GI), or bleeding on probing (BOP), in addition to
radio graphical findings. However, the findings from these
clinical parameters provide evidence regarding the previous
damage of the periodontium rather than clarifying the future
condition of the periodontal tissue. Therefore, it is very
important to find a method that can predict upcoming
periodontal disease. More reliable techniques for periodontal
diagnosis need to be researched [105] such as the MMP-8
chair-side testing that depends on the immunochromatog-
raphy principle which could be beneficial in supporting the
clinical diagnostic parameters during the maintenance phase
[6, 77]. Moreover, the results from such a test increase the
accuracy of the periodontal disease diagnosis and results of
unsuccessful treatments [106]. However, this test is fast, inex-
pensive, and easily performed and takes just 5 minutes [107].
2. Methodology
2.1. Inclusion and Exclusion Criteria. Inclusion criteria in
the current study included (a) clinical studies, (b) studies
performed on both systemically healthy and systemically
unhealthy subjects [patients with diabetes mellitus (DM),
coronary heart disease, or rheumatoid arthritis (RA)] with
periodontal disease, (c) studies performed on smokers, anx-
ious, or pregnant subjects, (d) studies published only in the
English language, and (e) studies clarifying the methodol-
ogy for GCF sample collection and biomarkers analytical
techniques. Exclusion criteria included studies specifically
designed to investigate the biomarkers in peri-implant sulcus
fluid (PISF), letters to the editor, historic reviews, and
commentaries.
2.2. Search Protocol. PubMed, Google Scholar, and Web of
Science databases from 2005 to 2015 were searched using
combinations of the following keywords: “periodontal dis-
ease”, “periodontitis”, “oral biomarkers”, “biomarkers”, and
“gingival crevicular fluids”. Titles and abstracts of studies
were identified using the above-described protocol, selected
by the authors, and checked for agreement. Full texts of
the studies were determined by title and abstract and then
independently assessed by the authors (Zeyad Nazar Majeed,
Dasan Swaminathan, A. M. Alabsi, Koshy Philip, and Sar-
avanan Pushparajan) with reference to the inclusion and
exclusion criteria. Initially 2,765 publications were identified,
while only 97 studies which fulfilled the inclusion criteria
were included and processed for data extraction as shown in
the flow chart (Figure 1).
3. Gingival Crevicular Fluid
Collection Methods
3.1. Intracrevicular Washing Technique. The device used to
perform this method consists of two injection needles placed
one inside the other.Thismethod for GCF collectionwas well
described by Salonen and Paunio [108] and the main details
of the studies that utilized washing technique in their GCF
collection were briefly illustrated in Table 1.
3.2. Microcapillary Technique. A calibrated volumetric or
noncalibrated microcapillary pipette with known volume is
used to collect GCF. Pradeep et al. [23, 24] gave a good
description in their studies on how to perform this collection
technique. In this systematic review, 24 studies used this
technique (Table 2).
3.3. Absorption Technique. Table 3 summarized the most
important findings of the studies that used the absorp-
tion technique. Generally, this technique is divided into
extracrevicular (Figure 2) and intracrevicular (Figure 3).
The first one is performed by placing paper strips over the
gingival crevice to reduce trauma. The second method is the
intracrevicular technique which is the most commonly used.
It may be subdivided into superficial and deep, depending
on the depth of strip insertions into gingival sulcus or
periodontal pocket [109].
4. Results
A meta-analysis of the results was not carried out in this
systematic review because the heterogeneity of the reviewed
studies involved the following aspects: GCF sampling, analyt-
ical methods, and oral biomarkers used in the diagnosis and
monitoring of periodontal disease.
4.1. Sampling Methods. With regard to the techniques used
for GCF collection, 97 studies were included and illustrated
in our review (Tables 1, 2, and 3). 69 studies used paper strips
for GCF collection (Table 3), 24 studies used microcapillary
pipettes (Table 2), and only 4 studies utilized the gingival
washing method to collect their samples (Table 1).
4.2. Analytical Methods. As shown in Tables 1, 2, and 3 many
methods were employed to analyze GCF samples in order
to get the desired results. The ELISA analytical method was
clearly the preferred method in the majority of the studies.
Seventy-one out of the 97 studies that we reviewed used the
ELISA technique to analyze the GCF samples.
4.3. Biomarkers. Of the 97 studies, IL-1𝛽 (22 studies), MMP-
8 (19 studies), and TNF-𝛼 (18 studies) were reviewed. These
results indicated that these biomarkers concentrations could
be used to compare the different stages of periodontal disease
and/or assess the effectiveness of periodontal therapy.
Results on sampling and analytical methods and
biomarkers are summarized in Figure 4.
4.4. IL-1𝛽. A comparison of GCF IL-1𝛽 levels between
periodontally diseased patients and healthy subjects was
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Table 1: Summary of washing techniques used in the GCF collection.
Reference Analysis Markers Aim Main findings
[8]
ELISA,
spectrophotometer
(SPM)
IL-1𝛽, IL-18,
elastase
activity
To evaluate inflammatory activity in GCF
in RA patients and patients without RA.
To determine if the periodontal
inflammation reduced after RA treatment.
RA anti-inflammatory treatment reduced
periodontal inflammation.
[9]
Capillary zone
electrophoresis
coupled with laser
induced fluorescence
detection
(CZE-LIFD)
Arginine,
glutamate
To evaluate the glutamate and arginine
GCF levels in adult chronic periodontitis
(CP) patients against healthy controls.
To compare two types of microdialysis
probes: U-shaped probes and normal.
Arginine level was elevated and glutamate
level was decreased in CP patients,
compared to healthy subjects.
No statistical differences were found
between the U-shaped and normal
probes.
[10] Polymerase chainreaction
Host
𝛽-globin gene
fragments
To determine the expression of gene
fragments of the host 𝛽-globin in GCF at
different stages of periodontal disease.
Periodontal diseases have marked effect
on gene fragment expression in GCF.
Thus 𝛽-globin DNA could be used as a
biomarker for periodontal disease.
[11] ELISA MMP-8,MMP-9
To determine the association between the
existence of subgingival microorganisms in
certain locations and the GCF levels of
MMP-9 and MMP-8.
The existence of subgingival
microorganisms in GCF, mainly T.
denticola, increased the MMP-9 and
MMP-8 levels.
PubMed
(N = 89)
Web of 
Science
(N = 26)
Google 
Scholar
(N = 2,650)
Studies excluded after primary screening of 
titles and abstracts 
(N = 2,584)
Full-text articles assessed for eligibility following 
the inclusion criteria
(N = 152)
Studies included in 
this systematic 
review
N = 97
Records after duplicates removed
(N = 29)
Records 
screened
(N = 2,736)
Full-text articles excluded that did not 
follow the inclusion criteria
(N = 55)
Literature search from 2005 to 2015 using PubMed/Web of 
Science and Google Scholar databases
Figure 1: Flow chart for research strategy.
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Table 2: Summary of microcapillary techniques used in GCF collection.
Reference Analysis Markers Aim Main findings
[12] ELISA IL-1𝛽
To find the difference in the IL-1𝛽 levels
between healthy control and CP patients.
To find the relationship between clinical
parameters and IL-1𝛽 levels.
The levels of IL-1𝛽 increased in accordance
with progression of periodontal disease.
[13] ELISA Resistin
To measure and compare the levels of resistin
in GCF in healthy subjects, chronic
periodontitis, and diabetes mellitus type 2
(T2DM) patients.
The level of resistin increased in CP and T2DM
patients. Hereafter, the level of resistin in GCF
could be considered as a biomarker for
periodontitis in T2DM patients.
[14] ELISA TNF-𝛼
To measure TNF-𝛼 levels in GCF and in serum,
and to find the effect of periodontal disease on
TNF-𝛼 levels.
TNF-𝛼 level in GCF could be used as a
biomarker for periodontal disease.
[15] ELISA
Monocyte
chemoattrac-
tant protein
(MCP-1)
To determine MCP-1 levels in GCF, serum, and
saliva, and to evaluate the effect of periodontal
therapy on MCP-1 levels.
GCF and saliva MCP-1 levels could be used as
biomarkers to indicate the severity of
periodontal disease.
[16] ELISA ProstaglandinE2 (PGE2)
To evaluate PGE2 levels in GCF in healthy
subjects and patients with periodontal disease,
before and after treatment.
The levels of PGE2 positively correlated to the
severity of periodontal disease.
[17] SPM
Alkaline
phosphatase
(ALP)
To compare GCF ALP levels in patients with
CP before and after nonsurgical periodontal
treatment.
GCF ALP levels could monitor the periodontal
disease status and effect of nonsurgical
periodontal treatment.
[18] SPM ALP To measure the GCF ALP levels in differentperiodontal disease stages.
ALP levels increased with periodontal disease
progression.Thus it could be considered a good
biomarker for periodontal disease progression.
[19] ELISA Oncostatin M(OSM)
To determine the level of OSM in GCF of
gingivitis and CP patients and to evaluate the
effect of periodontal treatment on level of
OSM.
Levels of OSM correlated to the clinical
periodontal parameters (PD and CAL) and
could be used as a biomarker for periodontal
disease.
[20] ELISA Cortisol
To measure the levels of salivary and GCF
cortisol in anxious and nonanxious patients
with CP.
Anxiety had a positive effect on periodontal
disease and the levels of cortisol in GCF can be
considered a biomarker for CP.
[21] ELISA
Plasma
glutathione
peroxidase
(eGPx)
To determine the eGPx levels in GCF to clarify
the effect of oxidants and antioxidants on
periodontal disease.
There was a positive correlation between the
levels of eGPx in GCF and periodontal
diseases. eGPx could be considered as a marker
of oxidative stress in periodontal diseases.
[22] ELISA MCP-1
To evaluate the MCP-1 role during the
development of periodontal disease and to
evaluate the outcome of periodontal treatment
on the levels of MCP-1.
The levels of MCP-1 elevated in accordance
with the severity of periodontal disease.
Periodontal treatment reduced the MCP-1
levels in GCF.
[23] ELISA MCP-1, IL-18 To examine MCP-1 and IL-18 GCF levels incontrol and periodontally diseased patients.
IL-18 and MCP-1 levels positively correlated to
periodontal disease status.
[24] ELISA Pentraxin-3(PTX3)
To evaluate PTX3 levels in Plasma and GCF in
subjects with and without periodontal disease.
PTX3 levels in GCF could be considered as a
biomarker for periodontal disease.
[25] EIA Neopterin To determine if neopterin levels in GCFcorrelated with periodontal clinical parameters.
Neopterin increased proportionally with the
severity of periodontal disease and it could be
considered as a biomarker of periodontal
disease.
[26] ELISA C-reactiveprotein (CRP)
To measure the levels of CRP in different
periodontal disease stages.
Levels of GCF CRP and serum CRP elevated
proportionately to periodontal disease severity.
[27] EIA LeukotrieneB4 (LTB4)
To evaluate the relationship between
periodontal clinical parameters and GCF LTB4
levels from diseased sites, previous to and after
treatment of periodontitis.
GCF LTB4 levels increased with the severity of
periodontal disease and reduced after
nonsurgical periodontal treatment.
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Table 2: Continued.
Reference Analysis Markers Aim Main findings
[28]
Sandwich
enzyme
immunoassay
kit
Vascular
endothelial
growth factor
(VEGF)
To find the correlation between GCF
VEGF levels and the periodontal clinical
parameters.
To find if there was a correlation between
the levels of VEGF in GCF and serum.
There was a positive correlation between
the levels of VEGF in GCF and the
periodontal clinical parameters. The same
correlation was observed between the
levels of VEGF in GCF and serum.
[29] ELISA Visfatin
To determine the concentrations of
visfatin in GCF and serum in control and
periodontally diseased patients in the
presence and absence of T2DM.
Positive associations were observed
between the levels of visfatin and
periodontal disease in all study groups.
[30] ELISA IL-17, IL-18
To discover the role of IL-18, IL-17 in
different periodontal disease stages before
and after treatment.
IL-18 levels in GCF were found to
correlate with periodontal disease
severity, and periodontal treatments
caused a decline in its concentration.
IL-17 was not detected in the GCF.
[31] ELISA VEGF
To determine the level of VEGF in
different periodontal disease stages and to
explore the effect of treatment on VEGF
levels in GCF.
Levels of VEGF in GCF elevated in
relation to periodontal disease severity.
Periodontal therapy led to a decrease in
their levels.
[32] ELISA Visfatin
To measure the serum and GCF visfatin
levels.
To explain the role of scaling and root
planning on visfatin levels.
Visfatin levels increased in accordance
with disease progression and could be
used as biomarkers during the treatment
of periodontal disease.
[33] Enzyme assay ALP
To determine the existence and ALP
levels activity in GCF in different stages
of periodontal disease.
There was a relationship between
periodontal disease and ALP level.
[34] ELISA Cystatin C
To measure the level of cystatin C in
serum and GCF in different periodontal
disease stages.
Cystatin C levels in serum and GCF
correlated to the severity of periodontal
disease and reduced after treatment.
[35] ELISA Osteopontin(OPN)
To measure the relation between clinical
parameters and osteopontin (OPN) levels
in GCF.
To evaluate the effect of periodontal
treatment on OPN levels.
GCF OPN levels increased with the
severity of periodontal disease and the
treatment resulted in a decrease in OPN
levels.
conducted in order to explain the suitability of using IL-
1𝛽 as a biomarker for periodontal disease progression. In
this comparison, only 10 studies among the 22 studies were
included (Table 4), due to the exclusion of the studies that
did not show enough clinical data and the studies that were
conducted on periodontally diseased patients with systemic
diseases (e.g., diabetes mellitus) or any other conditions that
might affect the results (e.g., pregnant women and smokers).
IL-1𝛽 concentrations in all studies showed moderate to
high significant differences between the healthy subjects and
patients with CP or GAgP.
Of the 10 studies that were included to determine the
difference in IL-1𝛽 levels, only 3 studies [41, 51, 103] showed
differences in IL-1𝛽 levels between healthy subjects and
patients with gingivitis. However this difference was non-
significant.
4.5. MMP-8. For MMP-8 levels differences between healthy
and diseased subjects, only 4 studies fulfilled the inclusion
criteria, the same as for IL-1𝛽. All the studies (Table 5)
showed differences between healthy subjects andCP patients.
Although these differences were highly significant in the
studies done by Konopka et al. [67], Rai et al. [88], and Teles
et al. [98], it was not considered significant by Yakob et al. [11].
4.6. TNF-𝛼. For TNF-𝛼 levels differences between healthy
and diseased subjects, only 8 studies were included which
fulfilled the inclusion criteria (Table 6). Reis et al. [91] showed
that TNF-𝛼 levels were significantly higher in diseased sites
compared to nondiseased sites. Gokul [14] showed a highly
significant difference between healthy subjects and patients
with gingivitis and CP. Kurtis¸ et al. [70] showed highly
significant difference between healthy subjects and patients
with CP and GAgP. However, the other studies showed only
slight difference in TNF-𝛼 level between healthy and diseased
subjects.
Despite the similarity in results with the majority of
studies reviewed in this systematic review, there were still
different effects of biomarkers on periodontal disease. The
findings of the studies also determined how those biomarkers
could be utilized in the diagnosis or monitoring periodontal
disease status, as shown in Tables 4, 5, and 6. The present
study showed that there was variability in the findings
between investigators even when using the same analytical
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ve
ls
co
ul
d
no
tb
eu
se
d
as
ab
io
m
ar
ke
rf
or
pe
rio
do
nt
al
di
se
as
e.
[4
6]
El
ec
tro
ch
em
ilu
m
in
es
ce
nc
e
te
ch
ni
qu
e
O
ste
oc
al
ci
n
To
m
ea
su
re
sa
liv
a,
pl
as
m
a,
an
d
G
CF
os
te
oc
al
ci
n
le
ve
ls
an
d
co
rr
ela
te
th
em
w
ith
os
te
op
or
os
is
an
d
pe
rio
do
nt
iti
s.
G
CF
os
te
oc
al
ci
n
le
ve
ls
w
er
ea
ss
oc
ia
te
d
w
ith
pe
rio
do
nt
al
di
se
as
eo
nl
y.
[4
7]
EL
IS
A
,m
ul
tip
le
xe
d
be
ad
im
m
un
oa
ss
ay
(M
PB
I)
,
SP
M
IL
-1
𝛽
,-
18
,e
la
st
as
e,
M
M
P-
8,
-9
To
ev
al
ua
te
th
ee
ffe
ct
of
sc
al
in
g
an
d
ro
ot
pl
an
ni
ng
on
pe
rio
do
nt
al
sta
tu
sa
nd
on
th
el
ev
els
of
IL
-1
𝛽
,e
la
sta
se
,
M
M
P-
9,
an
d
M
M
P-
8
in
pa
tie
nt
sw
ith
an
d
w
ith
ou
t
T2
D
M
.
Sc
al
in
g
an
d
ro
ot
pl
an
ni
ng
re
du
ce
d
th
el
ev
el
so
f
IL
-1
𝛽
,e
la
st
as
e,
M
M
P-
9,
an
d
M
M
P-
8
in
bo
th
gr
ou
ps
.
[4
8]
EL
IS
A
TN
F𝛼
,R
A
N
KL
To
m
ea
su
re
th
eT
N
F𝛼
an
d
RA
N
KL
co
nc
en
tr
at
io
ns
in
G
CF
of
pa
tie
nt
sw
ith
A
gP
,a
fte
rp
ho
to
dy
na
m
ic
or
no
ns
ur
gi
ca
lp
er
io
do
nt
al
tre
at
m
en
t.
Bo
th
ty
pe
so
ft
re
at
m
en
th
ad
th
es
am
ei
nfl
ue
nc
eo
n
TN
F-
𝛼
an
d
RA
N
KL
co
nc
en
tr
at
io
ns
.
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Ta
bl
e
3:
C
on
tin
ue
d.
Re
fe
re
nc
e
A
na
ly
sis
M
ar
ke
rs
A
im
M
ai
n
fin
di
ng
s
[4
9]
M
PB
I
IL
-6
,-
4,
-1
0,
-1
3,
-1
7,
TN
F𝛼
,
m
ac
ro
ph
ag
ei
nfl
am
m
at
or
y
pr
ot
ei
n-
(M
IP
-)
1𝛼
,M
IP
-1
𝛽
,
M
CP
1,
re
gu
la
te
d
on
ac
tiv
at
io
n
no
rm
al
T-
ce
ll
ex
pr
es
se
d
an
d
se
cr
et
ed
(R
A
N
TE
S)
To
de
te
rm
in
et
he
eff
ec
to
fa
dj
un
ct
iv
e
su
b-
an
tim
ic
ro
bi
al
-d
os
ed
ox
yc
yc
lin
e(
SD
D
)o
n
th
el
oc
al
in
fla
m
m
at
or
y
re
sp
on
se
th
ro
ug
h
ch
em
ok
in
ea
nd
cy
to
ki
ne
le
ve
ls
in
G
CF
sa
m
pl
es
fro
m
CP
pa
tie
nt
s.
SD
D
ai
de
d
no
ns
ur
gi
ca
lp
er
io
do
nt
al
th
er
ap
y.
[5
0]
EL
IS
A
M
M
P-
8,
TI
M
P-
1
To
de
te
rm
in
et
he
eff
ec
to
fa
zi
th
ro
m
yc
in
in
ad
di
tio
n
to
sc
al
in
g
an
d
ro
ot
pl
an
ni
ng
in
th
et
re
at
m
en
to
f
pe
rio
do
nt
al
di
se
as
e.
A
zi
th
ro
m
yc
in
di
d
no
tp
re
se
nt
an
y
ad
va
nt
ag
eo
ve
r
sc
al
in
g
an
d
ro
ot
pl
an
ni
ng
.
[5
1]
EL
IS
A
M
uc
os
a-
as
so
ci
at
ed
ep
ith
eli
al
ch
em
ok
in
e(
CC
L2
8)
,I
L-
8,
IL
-1
𝛽
,
TN
F-
𝛼
To
de
te
rm
in
et
he
co
nc
en
tr
at
io
ns
of
CC
L2
8,
IL
-1
𝛽
,I
L-
8,
an
d
TN
F-
𝛼
in
G
CF
am
on
g
stu
dy
gr
ou
ps
.
CC
L2
8,
IL
-1
𝛽
,I
L-
8,
an
d
TN
F-
𝛼
co
nc
en
tr
at
io
ns
w
er
ee
le
va
te
d
in
ac
co
rd
an
ce
w
ith
th
es
ev
er
ity
of
pe
rio
do
nt
al
di
se
as
e.
[5
2]
Fl
ow
cy
to
m
et
ry
TN
F-
𝛼
,I
L-
1𝛽
,-
6,
-8
,-
10
,-
12
p7
0
To
es
tim
at
et
he
ou
tc
om
eo
fp
er
io
do
nt
al
tre
at
m
en
to
n
G
CF
an
d
se
ru
m
co
nc
en
tr
at
io
ns
of
m
an
y
cy
to
ki
ne
s
re
lat
ed
w
ith
pe
rio
do
nt
al
di
se
as
ea
nd
pr
em
at
ur
eb
irt
h.
G
CF
cy
to
ki
ne
le
ve
lr
ed
uc
ed
sig
ni
fic
an
tly
aft
er
pe
rio
do
nt
al
tre
at
m
en
t.
[5
3]
M
PB
I,
EL
IS
A
Pe
nt
ra
xi
n
3,
IL
-1
0,
-1
𝛽
,-
6,
-8
,
TN
F𝛼
To
es
tim
at
et
he
co
rr
el
at
io
n
be
tw
ee
n
cli
ni
ca
lp
er
io
do
nt
al
m
ea
su
re
m
en
ts
an
d
th
ec
on
ce
nt
ra
tio
ns
of
six
cy
to
ki
ne
s.
Th
er
ew
as
as
tro
ng
co
rr
el
at
io
n
be
tw
ee
n
pe
rio
do
nt
al
sta
tu
sa
nd
PT
X3
or
IL
-1
𝛽
le
ve
ls
in
G
CF
.
[5
4]
EL
IS
A
M
D
A
,S
O
D
,m
el
at
on
in
To
de
te
rm
in
eG
CF
co
nc
en
tr
at
io
ns
of
su
pe
ro
xi
de
di
sm
ut
as
e(
SO
D
),
m
al
on
di
al
de
hy
de
(M
D
A
),
an
d
m
el
at
on
in
in
G
A
gP
an
d
CP
pa
tie
nt
sa
so
xi
da
tiv
es
tre
ss
bi
om
ar
ke
rs
.
SO
D
,m
el
at
on
in
,a
nd
M
D
A
co
ul
d
be
us
ed
to
di
ffe
re
nt
ia
te
be
tw
ee
n
G
A
gP
an
d
CP
pa
tie
nt
s.
[5
5]
Fl
uo
ro
m
et
ric
ki
ts
M
M
P-
1,
M
M
P-
2,
M
M
P-
3,
M
M
P-
8,
M
M
P-
9,
M
M
P-
12
,
M
M
P-
13
To
m
ea
su
re
G
CF
M
M
Ps
le
ve
ls
aft
er
lo
ca
liz
ed
ag
gr
es
siv
e
pe
rio
do
nt
iti
s(
LA
gP
)t
re
at
m
en
t.
LA
gP
tre
at
m
en
tw
ith
SR
P
an
d
sy
ste
m
ic
an
tib
io
tic
s
w
as
ac
tiv
ei
n
re
du
ci
ng
lo
ca
ll
ev
els
of
sp
ec
ifi
cM
M
Ps
.
[5
6]
EL
IS
A
M
M
P-
8,
M
M
P-
9,
M
M
P-
13
To
ev
al
ua
te
w
he
th
er
th
ep
re
se
nc
eo
fp
er
io
do
nt
iti
sa
nd
m
et
ab
ol
ic
sy
nd
ro
m
ew
as
re
la
te
d
to
M
M
P
in
G
CF
in
th
e
Ko
re
an
co
m
m
un
ity
.
M
M
P
(-
13
,-
8,
-9
)i
nd
iv
id
ua
lly
co
rr
ela
te
d
to
th
e
pr
es
en
ce
of
pe
rio
do
nt
iti
sa
nd
m
et
ab
ol
ic
sy
nd
ro
m
e.
[5
7]
W
es
te
rn
im
m
un
ob
lo
t
M
M
P-
13
To
de
te
rm
in
et
he
ro
le
of
G
CF
M
M
P-
13
in
ad
ul
tC
P
pa
tie
nt
s.
Th
er
ew
as
sig
ni
fic
an
ti
nc
re
as
ei
n
M
M
P-
13
ac
tio
n
in
ad
va
nc
ed
pe
rio
do
nt
al
di
se
as
e.
[5
8]
EL
IS
A
IL
-2
3
To
de
te
rm
in
eG
CF
IL
-2
3
le
ve
ls
in
he
al
th
y
su
bj
ec
ts
an
d
pa
tie
nt
sw
ith
pe
rio
do
nt
al
di
se
as
e.
IL
-2
3
le
ve
ls
in
cr
ea
se
d
co
rr
es
po
nd
in
gl
y
to
pe
rio
do
nt
al
di
se
as
ep
ro
gr
es
sio
n.
[5
9]
EL
IS
A
TN
F𝛼
,s
ol
ub
le
TN
F
re
ce
pt
or
s1
an
d
2
To
ev
al
ua
te
TN
F-
𝛼
le
ve
l,
so
lu
bl
eT
N
F
re
ce
pt
or
s1
an
d
2
in
se
ru
m
an
d
G
CF
of
he
al
th
y
an
d
CP
pa
tie
nt
s.
Th
el
ev
els
be
tw
ee
n
th
et
w
o
TN
F
re
ce
pt
or
sw
er
e
di
sp
ro
po
rt
io
na
te
.
[6
0]
EL
IS
A
,
im
m
un
ot
ur
bi
di
m
et
ric
an
al
ys
is
St
em
ce
ll
fa
ct
or
(S
CF
),
hi
gh
-s
en
sit
iv
ity
C-
re
ac
tiv
e
pr
ot
ei
n
(h
s-
CR
P)
To
de
te
rm
in
et
he
re
lat
io
n
be
tw
ee
n
G
CF
an
d
se
ru
m
co
nc
en
tr
at
io
n
of
hs
-C
RP
an
d
SC
F
of
tw
o
CP
gr
ou
ps
of
w
hi
ch
on
ei
sw
ith
T2
D
M
an
d
th
eo
th
er
is
w
ith
ou
t.
SC
F
an
d
hs
-C
RP
co
nc
en
tr
at
io
ns
in
cr
ea
se
d
in
pa
tie
nt
sw
ith
T2
D
M
.
[6
1]
EL
IS
A
Ca
lp
ro
te
ct
in
To
ev
al
ua
te
th
el
ev
els
of
ca
lp
ro
te
ct
in
in
G
CF
in
G
A
gP
pa
tie
nt
sp
rio
rt
o
an
d
aft
er
pe
rio
do
nt
al
tre
at
m
en
t.
Le
ve
ls
of
ca
lp
ro
te
ct
in
w
er
ei
nd
ic
at
or
so
fd
ise
as
e
ac
tiv
ity
in
bo
th
su
bj
ec
ta
nd
sit
el
ev
els
.
[6
2]
EL
IS
A
M
ye
lo
pe
ro
xi
da
se
(M
PO
),
ca
lp
ro
te
ct
in
To
ob
se
rv
ec
al
pr
ot
ec
tin
le
ve
ls
in
G
CF
du
rin
g
th
er
ap
y
fo
rG
A
gP
.
To
de
te
rm
in
ea
co
rr
el
at
io
n
be
tw
ee
n
th
eM
PO
an
d
ca
lp
ro
te
ct
in
w
hi
ch
w
er
ea
lso
de
te
rm
in
ed
.
Le
ve
ls
of
ca
lp
ro
te
ct
in
in
G
CF
co
rr
el
at
ed
to
pe
rio
do
nt
al
di
se
as
es
ev
er
ity
an
d
de
cr
ea
se
d
in
co
nc
en
tr
at
io
n
aft
er
tre
at
m
en
t.
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Ta
bl
e
3:
C
on
tin
ue
d.
Re
fe
re
nc
e
A
na
ly
sis
M
ar
ke
rs
A
im
M
ai
n
fin
di
ng
s
[6
3]
H
PL
CG
Pl
at
ele
ta
ct
iv
at
in
g
fa
ct
or
(P
A
F)
To
de
te
rm
in
et
he
co
rr
el
at
io
n
be
tw
ee
n
PA
F
an
d
pe
rio
do
nt
al
he
al
in
g.
A
lte
ra
tio
ns
in
PA
F
le
ve
ls
in
G
CF
m
ig
ht
be
va
lu
ab
le
fo
ro
bs
er
vi
ng
th
er
eg
en
er
at
io
n
an
d
re
pa
ir
of
pe
rio
do
nt
al
tis
su
es
.
[6
4]
EL
IS
A
ch
on
dr
oi
tin
su
lfa
te
(C
S)
,A
LP
To
de
te
rm
in
et
he
ro
le
of
CS
,A
LP
le
ve
ls
in
es
tim
at
in
g
di
ffe
re
nt
pe
rio
do
nt
al
di
se
as
es
ta
ge
s.
Th
el
ev
el
of
CS
w
as
be
tte
rt
ha
n
th
eA
LP
le
ve
lf
or
de
te
rm
in
in
g
pe
rio
do
nt
al
di
se
as
es
ta
ge
s.
[6
5]
EL
IS
A
CS
W
F6
ep
ito
pe
To
ev
al
ua
te
G
CF
le
ve
ls
of
CS
W
F6
ep
ito
pe
in
he
al
th
y
an
d
pe
rio
do
nt
al
ly
di
se
as
ed
pa
tie
nt
s.
CS
W
F6
ep
ito
pe
le
ve
ls
po
sit
iv
ely
co
rr
el
at
ed
to
th
e
ad
va
nc
em
en
to
fp
er
io
do
nt
al
di
se
as
e.
[6
6]
EL
IS
A
M
M
P-
8,
-9
,O
PG
,C
RP
,I
L-
1𝛽
To
ev
al
ua
te
th
ep
er
fo
rm
an
ce
of
M
M
P-
8,
-9
,O
PG
,C
RP
,
an
d
IL
-1
𝛽
le
ve
ls
in
G
CF
as
ab
io
m
ar
ke
rf
or
pe
rio
do
nt
al
di
se
as
e.
M
M
P-
8,
-9
,O
PG
,C
RP
,a
nd
IL
-1
𝛽
le
ve
ls
co
ul
d
su
pp
or
tc
lin
ic
al
pa
ra
m
et
er
si
n
th
ed
ia
gn
os
is
of
pe
rio
do
nt
al
di
se
as
e.
[6
7]
EL
IS
A
IL
-1
𝛽
,I
L-
8,
M
M
P-
8
To
ev
al
ua
te
th
ei
nfl
ue
nc
eo
fS
RP
on
le
ve
ls
of
cy
to
ki
ne
s
in
G
CF
fro
m
CP
pa
tie
nt
s,
in
re
lat
io
n
to
cli
ni
ca
l
pa
ra
m
et
er
s.
SR
P
re
du
ce
d
th
eI
L-
8,
IL
-1
𝛽
,a
nd
M
M
P-
8
G
CF
le
ve
ls.
[6
8]
EL
IS
A
M
M
P-
8
To
de
te
rm
in
et
he
as
so
ci
at
io
n
be
tw
ee
n
M
M
P-
8
in
G
CF
an
d
th
es
ev
er
ity
of
pe
rio
do
nt
al
di
se
as
e.
Th
el
ev
el
of
ac
tiv
eM
M
P-
8
w
as
hi
gh
er
in
sit
es
w
ith
de
ep
er
po
ck
et
de
pt
h.
[6
9]
EL
IS
A
,
im
m
un
ot
ur
bi
di
m
et
ry
M
CP
-4
,h
s-
CR
P
To
in
ve
st
ig
at
eG
CF
an
d
se
ru
m
le
ve
ls
of
hs
-C
RP
an
d
M
CP
-4
am
on
g
he
al
th
y
an
d
pe
rio
do
nt
al
ly
di
se
as
ed
pa
tie
nt
s.
hs
-C
RP
an
d
M
CP
-4
le
ve
ls
in
cr
ea
se
d
fro
m
pe
rio
do
nt
al
he
al
th
y
to
pe
rio
do
nt
iti
s.
hs
-C
RP
an
d
M
CP
-4
co
ul
d
be
bi
om
ar
ke
rs
of
in
fla
m
m
at
io
n
in
pe
rio
do
nt
al
he
al
th
an
d
di
se
as
e.
[7
0]
EL
IS
A
M
CP
-1
,T
N
F-
𝛼
To
de
te
rm
in
ea
nd
co
rr
el
at
eG
CF
le
ve
ls
of
M
CP
-1
an
d
TN
F-
𝛼
in
CP
an
d
A
gP
pa
tie
nt
s.
G
CF
le
ve
ls
of
M
CP
-1
an
d
TN
F-
𝛼
sh
ow
ed
po
sit
iv
e
co
rr
el
at
io
n.
[7
1]
EL
IS
A
,fl
uo
ro
m
et
ric
m
et
ho
d
PG
E2
,t
hi
ob
ar
bi
tu
ric
ac
id
re
ac
tiv
es
ub
st
an
ce
(T
BA
RS
)
To
ev
al
ua
te
th
ee
ffe
ct
so
fS
RP
an
d
flu
rb
ip
ro
fe
n
in
sm
ok
er
sa
nd
no
ns
m
ok
er
si
n
CP
pa
tie
nt
so
n
tw
o
G
CF
bi
om
ar
ke
rs
.
PG
E2
an
d
TB
A
RS
le
ve
ls
in
sm
ok
er
sd
ec
re
as
ed
m
or
e
th
an
in
no
ns
m
ok
er
sa
fte
rt
he
flu
rb
ip
ro
fe
n
in
ta
ke
.
[7
2]
IF
M
A
M
M
P-
8
To
m
ea
su
re
th
el
ev
els
of
M
M
P-
8
in
G
CF
am
on
g
tw
o
CP
gr
ou
ps
(s
m
ok
er
sa
nd
no
ns
m
ok
er
s)
.
Th
el
ev
els
of
M
M
P-
8
co
ul
d
be
us
ed
in
th
e
m
on
ito
rin
g
of
pe
rio
do
nt
al
di
se
as
es
.
[7
3]
EL
IS
A
,I
FM
A
A
zu
ro
ci
di
n,
ch
em
ok
in
el
ig
an
d
5,
M
PO
,T
IM
P-
1M
M
P-
13
,-
14
To
de
te
rm
in
et
he
di
ag
no
st
ic
ac
cu
ra
cy
of
G
CF
bi
om
ar
ke
rs
.
To
co
m
pa
re
tw
o
an
al
yt
ic
al
te
ch
ni
qu
es
us
ed
to
m
ea
su
re
M
M
P-
8
le
ve
ls.
C
ol
la
ge
no
ly
tic
M
M
Ps
an
d
m
ye
lo
pe
ro
xi
da
se
(M
PO
)
co
ul
d
be
co
ns
id
er
ed
as
go
od
bi
om
ar
ke
rs
fo
r
pe
rio
do
nt
al
di
se
as
es
.I
FM
A
an
al
yt
ic
al
m
et
ho
d
w
as
m
or
ep
re
ci
se
th
an
EL
IS
A
.
[7
4]
EL
IS
A
,r
ad
io
im
m
un
oa
ss
ay
25
-H
yd
ro
xy
vi
ta
m
in
D
3,
os
te
oc
al
ci
n,
IL
-1
𝛽
,I
L-
6
To
in
ve
st
ig
at
et
he
eff
ec
to
fS
RP
on
th
el
ev
el
so
f
25
-h
yd
ro
xy
vi
ta
m
in
D
3
an
d
th
re
eo
th
er
bi
om
ar
ke
rs
in
G
A
gP
pa
tie
nt
s.
Pe
rio
do
nt
al
tre
at
m
en
tl
ed
to
re
du
ct
io
n
in
th
el
ev
el
s
of
25
-h
yd
ro
xy
vi
ta
m
in
D
3
an
d
IL
-1
𝛽
.
[7
5]
EL
IS
A
PG
E2
,I
L-
1,
TN
F-
𝛼
To
es
tim
at
et
he
eff
ec
to
fc
om
bi
ni
ng
tw
o
an
tib
ac
te
ria
l
dr
ug
si
n
in
iti
al
pe
rio
do
nt
al
tre
at
m
en
to
n
pe
rio
do
nt
al
pa
ra
m
et
er
sa
nd
ce
rt
ai
n
bi
om
ar
ke
rs
in
pa
tie
nt
sw
ith
ag
gr
es
siv
ep
er
io
do
nt
iti
s.
Bo
th
ty
pe
so
ft
re
at
m
en
th
ad
su
bs
ta
nt
ia
le
ffe
ct
on
pe
rio
do
nt
al
di
se
as
es
ta
tu
s.
[7
6]
EL
IS
A
,i
m
m
un
ob
lo
tti
ng
hC
A
P1
8/
LL
37
,C
S
To
qu
an
tif
y
G
CF
le
ve
ls
of
hC
A
P1
8/
LL
-3
7
an
d
CS
in
he
al
th
y,
CP
,a
nd
A
gP
stu
dy
gr
ou
ps
.
A
po
sit
iv
ec
or
re
la
tio
n
be
tw
ee
n
th
eC
S
an
d
hC
A
P1
8/
LL
-3
7
le
ve
ls
w
as
no
te
d
in
CP
pa
tie
nt
so
nl
y.
Disease Markers 9
Ta
bl
e
3:
C
on
tin
ue
d.
Re
fe
re
nc
e
A
na
ly
sis
M
ar
ke
rs
A
im
M
ai
n
fin
di
ng
s
[7
7]
M
M
P-
8
sp
ec
ifi
cc
ha
ir-
sid
e
di
p-
st
ic
k
te
st
M
M
P-
8
To
de
te
rm
in
et
he
ac
cu
ra
cy
of
M
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Figure 2: Extracrevicular GCF collection.
Figure 3: Intracrevicular GCF collection.
techniques. In order to clarify the differences in outcome, a
comparison was made among the studies that used the same
analytical methods (Tables 7 and 8).
As shown in Table 7, only five studies were included that
used the same analytical method (standard ELISA technique)
for quantitative determination of IL-1𝛽 concentrations. It was
quite noticeable that there were differences in the values of
the mean IL-1𝛽 concentrations between the studies within
the same study group (H, G, CP, and GAgP). For example,
the mean IL-1𝛽 concentration among healthy subjects in the
five studies showed differences in mean values: 49.81, 195.77,
36.44, 15.5, and 17.8732.
Only two studies were involved for comparing MMP-8
mean values (Table 8). Both showed relatively close results
in which there was a slight difference in the mean values of
MMP-8 in each study group (H, CP).
5. Discussion
This systematic review was designed to discover the most
common and accurate GCF collection and biomarker analyt-
ical methods and to determine the reliable biomarkers that
could be used to detect periodontal disease.
5.1. GCF Sampling Methods. This paper discussed the three
main methods of GCF collection: absorption, microcapillary
pipetting, and the washing method. There were variations in
GCF collection techniques in several of the clinical studies
that were reviewed.
5.1.1. Absorption Method. The differences could be summa-
rized as follows:
(i) The majority of the studies used paper strips which
were considered to be more efficient in GCF col-
lection because they could be inserted easily into
gingival sulcus or periodontal pockets, as well as for
their ability to absorb fluids. However, few studies
used paper points (size 30) to collect GCF samples
although it was shown that paper points and paper
strips had different absorption rates. A study done
by Guentsch et al. [110] indicated that cytokine levels
were higher when paper strips were used. Paper
points are more commonly used for subgingival
plaque collection in microbiological analysis.
(ii) The time in which the paper strips or paper points
were left in the sulcus varied between 30 seconds [68,
76, 111] and 1minute [112].The periodmost frequently
used was 30 seconds to decrease the risk of blood or
saliva contamination.
(iii) There were variations in the sites fromwhich the GCF
samples were collected. Many studies collected GCF
samples from diseased sites only [72] in patients with
periodontal disease, while other researchers collected
samples from both healthy and diseased sites [111].
It was thus important to note that the majority of the
studies showed that biomarker levels positively correlated
with the periodontal parameters (GI, PD, and CAL). At the
same time, it was clarified that healthy sites in individuals
with periodontal disease showed increased concentrations of
biomarkers in comparison to healthy sites in subjects without
periodontal disease. This could be because biomarkers were
affected by the bacterial composition of the neighboring
subgingival plaque [98] and the fact that the development of
periodontitis was site-specific [53].
5.1.2. Microcapillary Pipetting. The time needed to collect
GCF samples was related to the desired amount of GCF
required and also to the condition of the sample sites (dis-
eased or healthy). The majority of clinical studies collected
GCF samples by keeping the microcapillary pipettes at the
entry of the pocket for 10 minutes [22, 85]. From our
experience, this duration was sufficient if we collected the
GCF samples from diseased sites. However, collection of the
samples from healthy subjects or healthy sites in patients
with periodontitis required 30–50 minutes. This difference
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Methods used for GCF collection Biomarkers used in the studies 
Methods of analysis
4.12%
24.74%
71.13%
Paper strips
Microcapillary
Washing
18.50%
22.60%
19.50%
IL-1𝛽
MMP-8
TNF-𝛼
26.90%
73.10%
ELISA
Other methods
Figure 4: Results summary.
in collection time between healthy and diseased sites was
due to the flow of GCF which was positively related to the
severity of periodontal disease [113–115].The lengthy duration
needed to collect GCF when using microcapillary pipettes
was considered one of the limitations of this technique,
which could increase the possibility of saliva and blood
contamination. It would also require more effort from the
clinician and could be time-consuming for the subjects.
5.1.3.WashingMethod. The results of this review showed that
the washing technique of GCF collection were not common
due to the technique sensitive difficulties. Also, there was
a high rate of blood contamination due to the increased
possibility of gingival irritation.
5.2. GCF Analytical Method. In the absence of convincing
evidence and the deficiency of data from well-designed
studies that focused on the techniques used in the analysis of
GCF and after determining the advantages and disadvantages
of each technique, it was still difficult to declare that a specific
technique was better than others. This was especially so if we
considered the following aspects: (a) accuracy and efficiency
in biomarker detection and quantification, (b) feasibility, (c)
cost, and (d) time. It was clearly shown that the majority of
researchers used the ELISA technique in their clinical studies,
probably due to its simplicity. It is quite important to clarify
that the use of ELISA is not the most accurate technique.
For example, Leppilahti et al. [73] showed that the IFMA
technique is more accurate than using ELISA.
5.3. Oral Biomarkers for Periodontal Disease Analyzed from
GCF Sampling. To date, an accurate diagnosis depends
mainly on clinical periodontal examination, radiographic
examination, and laboratory tests for microbial analyses [116]
that permit a precise evaluation and analysis of bone and
attachment loss levels.These findings could be supplemented
14 Disease Markers
Ta
bl
e
4:
Su
m
m
ar
y
of
stu
di
es
to
co
m
pa
re
IL
-1
𝛽
co
nc
en
tr
at
io
ns
(p
g/
m
l).
Re
fe
re
nc
es
Sa
m
pl
es
iz
e
St
ud
y
de
sig
n
H
ea
lth
y
G
in
gi
vi
tis
CP
G
A
gP
M
ea
n
±
SD
or
ra
ng
e
[4
1]
20
H
,2
0G
,2
0C
P,
20
G
A
gP
Cr
os
s-
se
ct
io
na
l
49
.8
1(
13
.2
7
to
14
4.
64
)
45
.6
8
(8
.4
9
to
12
2.
09
)
12
8.
99
(2
7.7
0
to
39
3.
02
)
93
.7
8
(1
1.4
0
to
24
7.5
5)
[1
2]
30
H
,3
0C
P
Cr
os
s-
se
ct
io
na
l
19
5.
77
00
40
9.2
73
3
[5
1]
21
H
,2
1G
,2
1C
P,
21
G
A
gP
Cr
os
s-
se
ct
io
na
l
36
.4
4
±
8.
86
52
.1
0
±
7.
15
42
3
±
35
.2
4
11
0.
23
±
9.
20
[5
3]
50
CP
Cr
os
s-
se
ct
io
na
l
0.
20
±
0.
31
(h
ea
lth
y
sit
e)
4.
93
±
5.
27
(d
ise
as
ed
sit
e)
[6
6]
18
H
,3
2G
,2
8
m
ild
CP
,2
2
m
od
er
at
e-
se
ve
rC
P
Lo
ng
itu
di
na
li
nv
es
tig
at
io
n
11
8
(9
2–
99
8)
48
2
(1
5–
90
8)
pr
og
re
ss
in
g
di
se
as
ea
ct
iv
ity
[6
7]
21
H
,3
0C
P
In
te
rv
en
tio
n
15
.5
±
14
.0
72
.5
±
37
.0
[8
0]
25
H
,2
4G
A
gP
In
te
rv
en
tio
n
7.
0
±
3.
9
19
.3
±
10
.0
[9
8]
20
H
,2
0C
P
Cr
os
s-
se
ct
io
na
l
45
.6
±
35
.0
98
.8
±
42
.4
[9
9]
25
H
,3
1A
gP
Cr
os
s-
se
ct
io
na
l
18
.9
±
8.
4
36
.3
±
17
.8
[1
03
]
10
H
,2
5G
Cr
os
s-
se
ct
io
na
l
14
.0
00
0
17.
87
32
H
:h
ea
lth
y
su
bj
ec
ts,
G
:g
in
gi
vi
tis
,C
P:
ch
ro
ni
cp
er
io
do
nt
iti
s,
G
A
gP
:g
en
er
al
iz
ed
ag
gr
es
siv
ep
er
io
do
nt
iti
s.
Disease Markers 15
Table 5: Summary of studies to compare MMP-8 concentrations (pg/ml).
References Samples Study design Healthy Gingivitis CP GAgP
Mean ± SD
[67] 21H, 30CP Intervention 2.6 ± 2.6 18.6 ± 6.4
[88] 10H, 10CP Cross-sectional 4.13 ± 12.32 15.13 ± 12.46
[98] 20H, 20CP Cross-sectional 14.1 ± 15.1 34.7 ± 30.0
[11] 43H, 56CP Cross-sectional 234.80 ± 169.71 240.24 ± 146.83
by GCF analyses where, as many studies have suggested,
GCF is a source of bimolecular sampling to investigate the
condition of periodontal tissues [112, 117]. GCF ingredients
are composed of many components that have been described
as markers for periodontal disease development. These com-
prise host-derived enzymes, host-response modifiers, and
tissue breakdown products [64].
It is known that biomarkers are objective and measurable
characteristics of biological processes [118] and they can
support clinical evaluation, that is, if we fully understand the
normal physiology of the biological processes of periodontal
disease diagnosis and progression [119]. There are many
biomarkers that can be derived from different biofluids
such as blood, serum, saliva, and GCF and from different
sources such as microbial dental plaque biofilm, connective
tissue breakdown products, inflammatory mediators, and
host derivatives. For example, MMPs that exist in GCF,
saliva, mouth-rinses, and peri-implant sulcular fluid (PISF)
can be used to discover a novel chair-side and point-of-
care analytical test, which is a nontraumatic method for the
diagnosis of periodontal diseases [120, 121].
In this review we focused on GCF biomarkers because of
their close proximity to periodontal tissue which minimizes
the possibility of reflecting a response on other inflammatory
processes in the body.
Several studies have suggested that IL-1𝛽 levels can be
used as a good biomarker to differentiate between healthy and
chronic periodontitis sites [12, 41, 51, 53, 98].They can also be
used to discriminate healthy subjects from patients with AgP
[41, 51, 80, 99]. Owing to the slight differences in IL-1𝛽 levels
between healthy and gingivitis sites [41, 51, 103], it is difficult
to use them as indicators or predictors for disease initiation
from healthy status to gingivitis.
Much greater levels of MMP-8 in GCF have been
observed in periodontitis patients than in healthy subjects
[6, 67, 88, 98, 122, 123]. This variation in MMP-8 levels can
serve as an indicator for periodontal disease development.
Furthermore, Leppilahti et al. [72] found that the levels of
MMP-8 in GCF at baseline can predict the behavior ofMMP-
8 levels during the phase of maintenance.
Yakob et al. [11] however found that there were no
statistical differences between healthy and diseased groups,
attributing these findings to the differences in the methods
used for GCF collection.
The results of this review, as also indicated in many
studies, showed minimal increase in TNF-𝛼 levels from
healthy to periodontally diseased sites [59, 80, 99, 103].
In other studies there was substantial elevation in TNF-𝛼
concentration from healthy to diseased sites [14, 70, 91].Thus,
TNF-𝛼 concentrations may also be used as a predictor of
disease progression.
This systematic review aimed to explore the most rea-
sonable factors that lead to variability in the findings among
different studies even when using the same analytical tech-
niques. In order to achieve this, a comparison between the
mean values of two biomarkers (IL-1𝛽 and MMP-8) was
conducted (Tables 7 and 8). The studies that comprised
sufficient data such as sample numbers, clear analytical
techniques, number or amount of GCF samples, and accurate
assessment of the clinical diagnosis through the use of
clinical diagnostic parameters (PD, CAL, PI, BOP, and GI)
were included in this comparison. Studies that included
smokers and diabetic subjects were excluded to minimize
the effects on the results. For instance, clinical studies in
different populations showed that smoking increased the risk
of periodontitis and also that smokers had higher progression
and severity of periodontal disease [124]. Tymkiw et al.
[102] found that smoking inhibited the expression of many
biomarkers including proinflammatory chemokines, regula-
tors of T-cells, and natural killer cells.This inhibition resulted
in a decrease in the recruitment of many proinflammatory
cytokines and cells to the periodontally inflamed sites, which
caused unsuccessful protection against bacterial invasion.
Furthermore, the mechanisms that explain the asso-
ciation between diabetes and periodontitis are not fully
understood but encompass aspects of immune function,
inflammation, cytokine biology, and neutrophil activity [125].
Types 1 and 2 diabetes have been related to elevated levels of
inflammatory mediators [126], such as IL-1𝛽 [127] and TNF-
𝛼 [128].
Table 7 shows a wide variety in the mean values of IL-
1𝛽 concentrations in the studies. However, the majority of
investigators used similar parameters such as size of study
population which may affect mean and standard deviation,
GCF collection methods (mainly paper strips), analytical
techniques (standard ELISA), and clinical diagnostic param-
eters to categorize the study sample (mainly PD, CAL, PI, and
BOP).However, we have noticed that companiesmanufactur-
ing ELISA kits apply different protocols for measurements of
biomarkers and the kit reagents may vary in their detection
ability. Another contributing factor to this variability may be
the difference in the amount of the collectedGCFfluids, rang-
ing from 1–4 paper strips collected from each subject. Such
differences in GCF volumes may also cause wide variation in
detection rates of biomarkers. This can be supported by the
results in Table 8 which showed slight differences between the
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Table 8: Comparison of the mean of MMP-8 concentration between different studies using the same analytical techniques.
Study [67] [88]
ELISA kit Standard ELISA kit Standard ELISA kit
(Quantikine R & D Systems) (Quantikine R & D Systems)
GCF collection method Paper strips Paper strips
Number of subjects 21H, 30CP 10H, 10CP
Number of samples 1 1
Mean and SD for MMP-8 concentration
(pg/ml) and clinical parameters for CP patients
18.6 (6.4) 15.13 (12.46)
PD = 6.4 (0.6) PD = 6.9 (1.9)
CAL = 5.4 (0.9) CAL = 5.5 (1.3)
PI (%) = 64.4 (18.8) BOP (%) = 57.9 (14.6)
GI = 2.3 (0.8)
Mean and SD for MMP-8 concentration
(pg/ml) and clinical parameters for H subjects
2.6 (2.6) 4.13 (12.32)
PD = 1.5 (0.9) PD = 2.5 (1.9)
CAL ≤ 1 CAL = 1.9 (0.5)
PI (%) = 45.8 (12.7) BOP (%) = 5.32 (3.71)
GI = 0.7 (0.3)
biomarker mean values, as both studies used the same ELISA
kit protocol (R & D System) and an equal number of GCF
samples (1 paper strip).
6. Limitations
Due to the heterogeneity of strategies used in the reviewed
studies such as sampling, analyticalmethods, and biomarkers
used, a meta-analysis of the results was not possible.
7. Conclusion
In the case of GCF collection methods, paper strips are
the easiest and a more precise method. For GCF sample
analysis, it is difficult to determine the most accurate method
of analysis, but this review has noted that the majority of
researchers depended on ELISA technique.
It can be concluded that it is better to use more than
one biomarker in determining the inflammatory activity of
periodontal disease. IL-1𝛽 and MMP-8 can be considered
the most preferred cytokines for determining inflammatory
activity in the periodontium.
The collected GCF volume and different ELISA kit man-
ufacturing companies are the major causative factors for
variation among the investigators.
In general, it is still early to depend on oral biomarkers
alone in the diagnosis of periodontal disease, especially in
the absence of universal methods for the collection and
analysis of these biomarkers. However, it can be utilized to
support the clinical parameters which are the most reliable
diagnostic methods and also for monitoring periodontal
disease progression.
Recommendations for Future Studies
The aim for investigating oral biomarkers is to discover
the possibility of using them in the prediction, diagnosis,
and monitoring of periodontal diseases or at least to be
used as adjunctive to traditional periodontal examination
and diagnosis. We believe that, in order to achieve this,
researchers should take into consideration the following
recommendations in their future studies:
(1) The measurement of GCF biomarkers levels should
be done by using different collection and analytical
methods in order to determine the most accurate
technique that can be standardized universally.
(2) Comparison of GCF biomarkers levels in different
ethnic groups consisting of large sample size should
be considered in order to explore the effects of genetic
differences on biomarkers levels and also to enable
proper statistical analysis.
(3) The choice of biomarkers in GCF derived studies is
important. Biomarkers that are known to influence
the prediction and progression of periodontal dis-
eases should be investigated for statistical correlation
to each other. Examples of biomarkers which can
contribute to this are IL-1𝛽 and MMP-8 whereby
Salminen et al. [129] used three salivary biomarkers
together to diagnose periodontal disease.
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